Alzheimer's disease (AD) is the most common dementing illness of late life, and robs persons of vigorous activity and productivity in their later years. Future drug treatments may be capable of slowing the progression of the disease or even preventing its clinical appearance, and when such treatments become available, the ability to detect the illness in its earliest stages will be needed to take full advantage of them. The overall goal of this project is to test the use of structural magnetic resonance scanning and the tools of computational anatomy to distinguish nondemented subjects at elevated risk for developing dementia of the Alzheimer type (DAT) from age- and gender-matched comparison subjects. The primary strategy for identifying subjects at elevated risk for developing DAT will be having a parent with DAT; allelic status for the apolipoprotein E gene will be a secondary strategy. High resolution magnetic resonance (MR) scans will be collected from all subjects at entry into the study, and for subjects who are recruited during the first two years of the Project, repeat MR scans will be collected after three years.
The specific aims of the project include a comparison of the structural characteristics of the hippocampus, parahippocampal gyrus (including the entorhinal cortex) and cingulate gyrus (anterior and posterior segments) in nondemented subjects with (N = 120) and without (n = 120) a parent with DAT. The total group of subjects will then be resorted according to the number of E4 alleles for apolipoprotein E, and a comparison of subjects with or without one or more E4 alleles will be made. If there are neuroanatomical differences in the groups of subjects with and without one or more E4 alleles, then the impact of the apoE4 allele on the effect of having a parent with DAT will be investigated. In addition, we will determine whether there are correlations between neuroanatomical measures that discriminate between subjects at elevated risk for developing DAT and comparison subjects and other predictive variables assessed by other Projects.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
1P01AG026276-01
Application #
6989343
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Project Start
2005-07-01
Project End
2010-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
1
Fiscal Year
2005
Total Cost
$139,815
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Schindler, Suzanne E; Sutphen, Courtney L; Teunissen, Charlotte et al. (2018) Upward drift in cerebrospinal fluid amyloid ? 42 assay values for more than 10 years. Alzheimers Dement 14:62-70
Sato, Chihiro; Barthélemy, Nicolas R; Mawuenyega, Kwasi G et al. (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 98:861-864
Babulal, Ganesh M; Chen, Suzie; Williams, Monique M et al. (2018) Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. J Alzheimers Dis 66:1213-1221
Millar, Peter R; Balota, David A; Bishara, Anthony J et al. (2018) Multinomial models reveal deficits of two distinct controlled retrieval processes in aging and very mild Alzheimer disease. Mem Cognit 46:1058-1075
Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98
Vlassenko, Andrei G; Gordon, Brian A; Goyal, Manu S et al. (2018) Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiol Aging 67:95-98
Roe, Catherine M; Babulal, Ganesh M; Stout, Sarah H et al. (2018) Using the A/T/N Framework to Examine Driving in Preclinical AD. Geriatrics (Basel) 3:
Stout, Sarah H; Babulal, Ganesh M; Ma, Chunyu et al. (2018) Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. Alzheimers Dement 14:610-616
Chen, Jason A; Fears, Scott C; Jasinska, Anna J et al. (2018) Neurodegenerative disease biomarkers A?1-40, A?1-42, tau, and p-tau181 in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathy. Brain Behav 8:e00903
Day, Gregory S; Musiek, Erik S; Morris, John C (2018) Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. Alzheimer Dis Assoc Disord 32:291-297

Showing the most recent 10 out of 352 publications